StockData
Tonix Pharmaceuticals Holding Corp. logo

Tonix Pharmaceuticals Holding Corp. (TNXP) stock

TNXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3083% below fair value
$2.94+0.06 (+2.08%)

Close on Nov 17, 2026Market cap $50.42MP/E –Yield –

Tonix Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

Tonix Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $63.86M, up 79.0% year over year. For fiscal 2025 it was $44.49M, up 11.3% from the year before. Over ten years it grew 2.3% a year on average. The highest annual figure on record is $86.66M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$44.49M+11.3%
FY2024Dec 31, 2024$39.97M-53.9%
FY2023Dec 31, 2023$86.66M+5.8%
FY2022Dec 31, 2022$81.88M+18.9%
FY2021Dec 31, 2021$68.84M+90.4%
FY2020Dec 31, 2020$36.16M+98.8%
FY2019Dec 31, 2019$18.19M+3.6%
FY2018Dec 31, 2018$17.56M+31.6%
FY2017Dec 31, 2017$13.34M-53.2%
FY2016Dec 31, 2016$28.53M-19.6%
FY2015Dec 31, 2015$35.50M+90.7%
FY2014Dec 31, 2014$18.62M+300.4%
FY2013Dec 31, 2013$4.65M+80.0%
FY2012Dec 31, 2012$2.58M+123.1%
FY2011Dec 31, 2011$1.16M+98.2%
FY2010Dec 31, 2010$584.30K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$19.42M+79.5%
Q1 FY2026Mar 31, 2026$18.21M+144.9%
Q4 FY2025Dec 31, 2025$16.94M+104.2%
Q3 FY2025Sep 30, 2025$9.29M+1.9%
Q2 FY2025Jun 30, 2025$10.82M+11.6%
Q1 FY2025Mar 31, 2025$7.44M-42.2%
Q4 FY2024Dec 31, 2024$8.30M-51.5%
Q3 FY2024Sep 30, 2024$9.11M-56.7%
Q2 FY2024Jun 30, 2024$9.70M-55.9%
Q1 FY2024Mar 31, 2024$12.86M-51.5%
Q4 FY2023Dec 31, 2023$17.12M-30.6%
Q3 FY2023Sep 30, 2023$21.05M-5.2%
Q2 FY2023Jun 30, 2023$21.98M+32.6%
Q1 FY2023Mar 31, 2023$26.51M+43.9%
Q4 FY2022Dec 31, 2022$24.67M+10.7%
Q3 FY2022Sep 30, 2022$22.20M+69.7%
Q2 FY2022Jun 30, 2022$16.58M-8.6%
Q1 FY2022Mar 31, 2022$18.42M+20.2%
Q4 FY2021Dec 31, 2021$22.30M+84.3%
Q3 FY2021Sep 30, 2021$13.08M+48.4%
Q2 FY2021Jun 30, 2021$18.13M+71.5%
Q1 FY2021Mar 31, 2021$15.33M+227.8%
Q4 FY2020Dec 31, 2020$12.10M+112.6%
Q3 FY2020Sep 30, 2020$8.81M+74.4%
Q2 FY2020Jun 30, 2020$10.57M+197.4%
Q1 FY2020Mar 31, 2020$4.68M+20.0%
Q4 FY2019Dec 31, 2019$5.69M+12.5%
Q3 FY2019Sep 30, 2019$5.05M+54.8%
Q2 FY2019Jun 30, 2019$3.55M-12.6%
Q1 FY2019Mar 31, 2019$3.90M-24.6%
Q4 FY2018Dec 31, 2018$5.06M+39.2%
Q3 FY2018Sep 30, 2018$3.26M-16.5%
Q2 FY2018Jun 30, 2018$4.07M+44.9%
Q1 FY2018Mar 31, 2018$5.17M+72.7%
Q4 FY2017Dec 31, 2017$3.63M-25.5%
Q3 FY2017Sep 30, 2017$3.91M-28.5%
Q2 FY2017Jun 30, 2017$2.81M–
Q1 FY2017Mar 31, 2017$2.99M–
Q4 FY2016Dec 31, 2016$4.88M–
Q3 FY2016Sep 30, 2016$5.47M–

More Tonix Pharmaceuticals figures

See a number that looks wrong?